Philippe Paul Juin

This study identifies CK1 as a bimodal regulator of the cGAS-STING pathway, showing it both promotes DNA sensing and facilitates signaling termination, with therapeutic implications for cancer.

This study shows that the NOXA/MCL-1 axis determines whether breast cancer cells undergo apoptosis or pyroptosis in response to anti-mitotic treatment, and influences the inflammatory secretome.

The paper identifies an EGFR/TBK1-dependent mitochondrial quality control mechanism that contributes to acquired resistance to temozolomide in glioma cells.

The paper shows that tail anchors of BCL-xL and PUMA modulate BH3-in-groove interactions, affecting BH3 mimetic antagonism and cell survival.

This study shows primary cilia in TNBC cells contribute to chemoresistance by supporting EMT-driven heterogeneity and stemness, and inhibiting ciliogenesis reduces this resistance.

This study shows that MCL-1 regulates the switch between myofibroblastic and pro-angiogenic features in breast cancer-associated fibroblasts, with implications for treatment response.

The paper shows antimitotic chemotherapy induces a NF-kB secretory phenotype in triple-negative breast cancer, promoting immunosuppressive CXCR2+ neutrophil chemotaxis, and demonstrates that CXCR2 inhibition enhances antitumor immunity.

This study shows that BCL-xL promotes chemotherapy resistance in TNBC cells, and CAFs reduce the effectiveness of chemotherapy combined with BCL-xL inhibition.

The paper develops a machine learning predictor for TNBC subtyping using a limited number of probes, achieving better performance with gradient boosting.